Capricor Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of spectrum of diseases and disorders. Its lead candidate, CAP-1002, an allogeneic cardiac-derived cell therapy, which has completed phase III clinical trial for the treatment of patients with late-stage Duchenne muscular dystrophy (DMD); and CAP-1002, which is in Phase II clinical trial for the treatment of cytokine storm associated with SARS-CoV-2. The company also develops CAP-2003 that is in pre-clinical development for the treatment of trauma related injuries and conditions; and two vaccine candidates, which are in development stage for the potential prevention of COVID-19. It collaborates with Lonza Houston, Inc. for the clinical manufacturing of CAP-1002, its cell therapy candidate for the treatment of DMD and other indications. The company was founded in 2005 and is headquartered in San Diego, California.

• Download SqueezeTrigger (TM) Report
• Download FrictionFactor Report
• Download Daily Short Volume Report
• Download Real-Time Short Volume Tool
• Download Failures to Deliver

• [06/26/2025 07:19 PDT] CAPR Expected to Trade Up After Bullish Patterns Develop
• [06/25/2025 12:42 PDT] CAPR SqueezeTrigger Price is $0.00. There is $0 That Short Sellers Still Need To Cover.
• [06/23/2025 11:45 PDT] Capricor Therapeutics, Inc. (NASDAQ:CAPR), Down By 100% ($8.3) From $8.3 After BUYINS.NET Report Predicted Stock Would Go Down Due To Bearish Conditions
• [06/23/2025 07:25 PDT] CAPR Expected to Trade Down Short Term
• [06/20/2025 10:30 PDT] Capricor Therapeutics, Inc. (NASDAQ:CAPR), Down By 100% ($11.76) From $11.76 After BUYINS.NET Report Predicted Stock Would Go Down Due To Bearish Conditions
• [06/16/2025 13:58 PDT] Capricor Therapeutics, Inc. (NASDAQ:CAPR), Down By 100% ($13.38) From $13.38 After BUYINS.NET Report Predicted Stock Would Go Down Due To Bearish Conditions
• [06/16/2025 07:10 PDT] CAPR Expected to Trade Down After Bearish Patterns Develop
• [06/10/2025 06:55 PDT] CAPR Expected to Trade Down After Bearish Patterns Develop
• [06/09/2025 07:20 PDT] CAPR Expected to Trade Up Short Term
• [06/05/2025 12:42 PDT] Capricor Therapeutics, Inc. (NASDAQ:CAPR), Up By 100% ($11) From $10.995 After BUYINS.NET Report Predicted Stock Would Go Up Due To Bullish Conditions
• [05/21/2025 11:07 PDT] Capricor Therapeutics, Inc. (NASDAQ:CAPR), Up By 100% ($9.36) After BUYINS.NET SqueezeTrigger Report Released on Thursday, May 15th 2025 at a Price of $9.355.
• [05/21/2025 07:27 PDT] CAPR Expected to Trade Up After Bullish Patterns Develop
• [05/15/2025 15:33 PDT] CAPR SqueezeTrigger Price is $0.00. There is $0 That Short Sellers Still Need To Cover.
• [05/15/2025 14:55 PDT] Capricor Therapeutics, Inc. (NASDAQ:CAPR), Up By 100% ($7.59) From $7.59 After BUYINS.NET Report Predicted Stock Would Go Up Due To Bullish Conditions
• [05/15/2025 06:53 PDT] CAPR Expected to Trade Up After Bullish Patterns Develop
• [05/13/2025 10:30 PDT] Capricor Therapeutics, Inc. (NASDAQ:CAPR), Up By 100% ($6.34) From $6.34 After BUYINS.NET Report Predicted Stock Would Go Up Due To Bullish Conditions
• [05/12/2025 07:18 PDT] CAPR Expected to Trade Up After Bullish Patterns Develop
• [05/08/2025 07:12 PDT] CAPR Expected to Trade Down After Bearish Patterns Develop